A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with hepatitisC virus-related decompensated cirrhosis.

Abstract

The real-world efficacy of sofosbuvir/velpatasvir treatment for patients with hepatitisC virus-related decompensated cirrhosis is unclear. We aimed to identify factors that improve liver functional reserve after treatment. This was a multicenter retrospective study of 12-week sofosbuvir/velpatasvir treatment. A total of 48 patients with Child-Pugh (CP) class B or C were enrolled at 11 institutions. We evaluated changes in liver functional reserve at 24weeks post-treatment. At baseline, 40 and eight patients were CP class B and C, respectively. The overall rate of sustained virologic response 12weeks post-treatment was 95.8% (46/48). Serum albumin, alanine aminotransferase and α-fetoprotein levels, and the FIB-4 index were significantly improved post-treatment (P<0.05). Among patients who achieved sustained virologic response 12weeks post-treatment, those with CP class A increased from 0 to 24 patients (56%) at 24weeks post-treatment. In multivariate analysis, body mass index (BMI) ≥25 was an independent factor that inhibited CP class improvement (P<0.05). In decision tree analysis, after treatment, the initial divergent variable for CP class improvement was hepatic encephalopathy, followed by serum sodium level and BMI. Sofosbuvir/velpatasvir treatment improved the liver functional reserve in patients with hepatitisC virus-related decompensated cirrhosis at 24weeks post-treatment. However, BMI ≥25 inhibited improvement in CP class. Additionally, decision tree analysis revealed that a combination of hepatic encephalopathy, serum sodium levels, and BMI were diversity profiles associated with no improvement in liver functional reserve after the treatment.